Selinexor

Evidence Level: L5

Predicted Indications: 1

Selinexor

Pharmacist Assessment Report

Selinexor: From an Unspecified Original Indication to Drug-Induced Osteoporosis

One-Sentence Summary

Selinexor is marketed in Canada under the brand name XPOVIO, but the data compiled for this report do not list its approved indication text. The TxGNN model predicts it may be effective for drug-induced osteoporosis, but there are currently no clinical trials and no publications supporting this direction, so the prediction rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not available in the data compiled for this report
Predicted New Indication	Drug-induced osteoporosis
TxGNN Prediction Score	0.9922
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Selinexor is generally known as an inhibitor of XPO1 (exportin-1), a selective inhibitor of nuclear export. This general knowledge has not been verified against the data compiled for this report.

A possible but unverified link is that XPO1 inhibition changes the nuclear retention of tumour suppressors and signalling regulators (for example in the NF-kB and Wnt pathways). These pathways are involved in bone remodelling, so in theory they could affect osteoclast and osteoblast activity. The data give no indication of whether the effect would be protective or harmful.

The prediction should be treated with caution. Drug-induced osteoporosis is a drug-adverse-effect category, so the TxGNN model (deep learning) score of 0.9922 may reflect similarities the model learned between related diseases, not biological evidence. At this point the link is a hypothesis only and needs experimental validation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02527677	XPOVIO	Not listed	Not listed

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (XPO1 / nuclear export inhibitor), based on general drug knowledge; not confirmed in the compiled data
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions (typically CBC, liver and renal function, electrolytes)
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: The interaction query found 81 interacting drugs in total. The first 20 returned are shown below, and the full list was not reviewed.
- Major: Deferiprone, Samarium (153Sm) lexidronam, Adalimumab, Baricitinib, Certolizumab pegol, Cladribine, Clozapine
- Moderate: Strontium chloride Sr-89, Roflumilast, Chloramphenicol (systemic and ophthalmic), Zidovudine, Alefacept, Alemtuzumab, Anakinra, Azathioprine, Canakinumab, tetanus toxoid vaccine, anthrax vaccine, live oral cholera vaccine
Many of the listed drugs are immunosuppressants, myelosuppressive agents or live vaccines, so combined use needs careful review.

For warnings and contraindications, please refer to the package insert, as no label data were available.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a high model score (0.9922) but no clinical trials, no literature and no verified mechanism, which places it at evidence level L5. Drug-induced osteoporosis is also an adverse-effect category, so the prediction may reflect a TxGNN model (deep learning) artefact. The label warnings and contraindications are missing, so safety screening cannot proceed.

To proceed, the following is needed:

Health Canada package insert (warnings, contraindications and approved indication), which currently blocks safety screening
Mechanism of action data from DrugBank, to support analysis of the mechanistic link
Preclinical or literature evidence on the effect of XPO1 inhibition on bone metabolism, including whether the effect is protective or harmful
Review of the full list of 81 drug interactions
Confirmation of the original indication, dosage form and manufacturer for the XPOVIO licence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.